Core 1: Biospecimen/Pathology

摘要-生物标本/病理学核心（核心1） 杜克癌症健康差异的生物标本/病理学核心P20 SPORE（DCHD）利用并 位于杜克癌症研究所的BioRepository & Precision Pathology Center（BRPC）。BRPC是一个 杜克癌症研究所的共享资源，部分由杜克癌症中心支持补助金支持 （5P30-CA014236-45）。这个由国家癌症研究所资助的共享服务中心获得了患者的广泛同意， 组织样本捐赠和获取，处理和储存液体和组织生物标本，支持 杜克的“活体生物库”与杜克患者来源的异种移植和原代肿瘤细胞培养服务，以及 实施生物信息学和临床策略，以实现精确的样本和模型注释。对于DCHD， 核心将有效地提供高质量的组织，血液和液体为基础的生物标本和处理服务， 要求调查人员，并继续调整做法，研究人员的需要演变（目标1）;支持目前的 和未来的DCHD P20项目，通过扩展组织采购、处理 和样本管理（目标2）;教育地方、区域和国家社区， 生物医学研究中可用的生物标本，以提高标本和数据的可用性， 代表性不足的少数群体（目标3）。该杜克BRPC最近被授予NCI UM 1加入 合作人类组织网络（CHTN）（www.chtn.org）;该生物储存库网络将支持 来自全国各地的更深层次的队列生成。就建议的工程项目而言，我们会提供适当的 来自多个人种/种族的肺癌标本和相关数据（项目1），以及胃活检 阳性H.幽门螺杆菌从黑人患者（项目2）。将评估未来试点项目的需求， 可行性;考虑到BRPC现有的图书馆，最近对代表性不足的少数民族的关注，以及CHTN 参与，广泛的癌症差异研究应该是可能的。该核心完全集成到 DCHD，并对其成功至关重要。

ABSTRACT – Biospecimen/Pathology Core (Core 1) The Biospecimen/Pathology Core of the Duke Cancer Health Disparities P20 SPORE (DCHD) leverages and is housed in the Duke Cancer Institute’s BioRepository & Precision Pathology Center (BRPC). The BRPC is a Shared Resource of the Duke Cancer Institute and supported in part by the Duke Cancer Center Support Grant (5P30-CA014236-45). This NCI-funded shared service center obtains broad consent from patients for blood and tissue sample donation and procures, processes and banks both liquid and tissue biospecimens, supports Duke’s “living biobank” with the Duke Patient-Derived Xenograft and Primary Tumor Cell Culture Services, and implements bioinformatic and clinical strategies for precise sample and model annotation. For the DCHD, the Core will efficiently provide high-quality tissue, blood and fluid-based biospecimens and processing services to requesting investigators, and continue to adjust practices as researcher needs evolve (Aim 1); support current and future DCHD P20 projects through expansion of existing best practices in tissue procurement, processing, and sample management (Aim 2); and educate the local, regional and national community on the importance of available biospecimens in biomedical research to enhance availability of specimens and data from underrepresented minorities (Aim 3). The Duke BRPC has recently been awarded an NCI UM1 to join the Cooperative Human Tissue Network (CHTN)(www.chtn.org); this network of biorepositories will support deeper cohort generation from across the country. For the proposed Projects, we will provide appropriate lung cancer specimens and associated data from multiple races/ethnicities (Project 1), and stomach biopsies positive for H. pylori from Black patients (Project 2). The needs of future Pilot Projects will be assessed for feasibility; given the BRPC’s existing library, a recent focus on underrepresented minority inclusion, and CHTN participation, a wide range of cancer disparities research should be possible. This Core is fully integrated into the DCHD and is critical for its success.